Vanderbilt Center for Diabetes Translation Research

范德比尔特糖尿病翻译研究中心

• 批准号: 9354429
• 负责人: TOM A ELASY
• 金额: $ 66.19万
• 依托单位: VANDERBILT UNIVERSITY MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-09-01 至 2021-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9354429
• 关键词: Academic Medical Centers; Award; Behavior Therapy; Behavioral; Caring; Clinical; Clinical Trials; Collaborations; Communities; Community Health; Community Outreach; Development; Diabetes Mellitus; Diabetes prevention; Direct Costs; Doctor of Medicine; Doctor of Philosophy; Foundations; Funding; Goals; Individual; Institution; Insulin-Dependent Diabetes Mellitus; K-Series Research Career Programs; Knowledge; Lead; Leadership; Manuscripts; Medial; Methods; Modification; National Institute of Diabetes and Digestive and Kidney Diseases; Non-Insulin-Dependent Diabetes Mellitus; Obesity; Publishing; Research; Research Personnel; Risk; Secure; Services; Structure; Technology; Translational Research; Translations; United States National Institutes of Health; base; cardiovascular risk factor; college; design; diabetes control; diabetes risk; education research; effective intervention; ethnic minority population; glycemic control; health disparity; high risk; high risk population; medical schools; prevent; programs; racial minority; success

Center Overview Project Summary/Abstract Clinical trials have established that glycemic control and cardiovascular risk factor modification can reduce the risk of complications of type 1 and type 2 diabetes. In addition, behavioral strategies have been shown to delay or prevent the development of type 2 diabetes in individuals at high risk for diabetes. Despite the clarity of evidence, many individuals with diabetes do not meet the recommended goals of diabetes care. There is an unequivocal gap between evidence and real-world diabetes prevention and treatment, and this gap is particular evident in many racial and ethnic minorities. Investigators at the Vanderbilt University Medical Center and Meharry Medical College propose a renewal to our Center for Diabetes Translation Research ( https://labnodes.vanderbilt.edu/cdtr ) to bridge this gap by building on our success in type II translation research. This renewal proposal is based on a highly productive initial five years and a plan for the next cycle that maintains continuity with our excellent leadership while introducing change to reflect the changing needs of our research base. During the past five years our research base has significantly enlarged (from 23 to 38), been well funded (annual direct costs from NIDDK alone of nearly five million), and published important manuscripts (136 cited). Our P&F program has been extremely successful (8 investigators funded for 30K/year for two years) in that four investigators have already received either a K award or a DP3 award and a fifth awardee has secured a RO1. We believe our P&F program, owing to the ability to leverage institutional matching funds and the ability to extend over two years, has been one of the most successful aspects of the Center. Our enrichment program is extensive and includes collaborations with multiple entities across campus. We propose to build on the excellence of the past five years by maintaining continuity in our core structure and leadership while introducing a new core (Behavioral Intervention Technologies and Services Core) and leader (Chandra Osborn, Ph.D.) to reflect the expanding research base that utilizes technology for behavioral interventions. We maintain a focus on health disparities through our long standing relationship with Meharry Medical College and build on that foundation by introducing a new leader (Consuelo Wilkins, M.D.) to lead our enrichment core. Dr. Wilkins leads the Meharry-Vanderbilt Alliance (https://medschool.vanderbilt.edu/meharry- vanderbilt/) which explicity promotes collaboration between our two institutions to promote clinical and community-engaged collaboration, education and research. These additions build on our theme of reducing health disparities while expanding on our efforts to advance knowledge in behavioral intervention technologies.

中心概况项目概要/摘要 临床试验已经确定，血糖控制和心血管危险因素的修改可以减少 1型糖尿病的治疗方法有哪些此外，行为策略已被证明可以延迟 或预防糖尿病高危个体发生2型糖尿病。尽管清晰的 证据表明，许多糖尿病患者没有达到糖尿病护理的推荐目标。有一个 证据和现实世界的糖尿病预防和治疗之间存在明确的差距，这种差距是特别的 这在许多少数民族和种族中是显而易见的。 范德比尔特大学医学中心和梅哈里医学院的调查人员建议更新， 我们的糖尿病翻译研究中心（https://labnodes.vanderbilt.edu/cdtr）通过以下方式弥合这一差距： 基于我们在第二类翻译研究中的成功。这一更新建议是基于一个高生产力的 第一个五年计划和下一个周期的计划，保持我们出色领导的连续性， 引入变革，以反映我们研究基地不断变化的需求。在过去的五年里，我们的研究 基地已大大扩大（从23个增加到38个），资金充足（仅NIDDK每年的直接费用就达 近500万），并发表了重要的手稿（136引用）。我们的P&F计划已经非常 成功（8名调查员每年3万美元，为期两年），因为4名调查员已经收到 K奖或DP 3奖，第五名获奖者获得RO 1。我们相信我们的P&F计划，由于 到能够利用机构配套资金，并能够延长两年，一直是一个 该中心最成功的方面。我们的丰富计划是广泛的，包括合作 在校园里有多个实体 我们建议在过去五年的卓越成就基础上再接再厉，保持核心架构的延续性， 领导力，同时引入新的核心（行为干预技术和服务核心）和领导者 （钱德拉奥斯本博士）以反映不断扩大的研究基础， 干预措施。我们通过与Meharry的长期合作关系， 医学院，并在此基础上引入一个新的领导人（Consuelo威尔金斯，医学博士）领导我们的 浓缩核心威尔金斯博士领导着梅哈里-范德比尔特联盟（https：medschool.vanderbilt.edu/meharry- 范德比尔特/），明确促进我们两个机构之间的合作，以促进临床和 社区参与的合作、教育和研究。这些增加的内容建立在我们减少 健康差距，同时扩大我们在行为干预技术方面的知识。